Protagonist Therapeutics (PTGX) Stock Chart & Stock Price History $40.69 -0.77 (-1.86%) (As of 12/17/2024 ET) Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Protagonist Therapeutics Stock Price Performance 5 Day Performance-0.95%1 Month Performance+0.74%3 Month Performance-9.11%6 Month Performance+24.85%Year-To-Date Performance+77.45%1 Year Performance+96.29% Receive PTGX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Do this Before Elon’s Reveal on January 22nd (Ad)Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. PTGX Stock Chart for Wednesday, December, 18, 2024 PTGX Chart by TradingView Protagonist Therapeutics Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization12/17/2024$41.46$40.69-1.86%$41.13$39.63512,279 shs$2.43 billion12/16/2024$41.08$41.46+0.93%$41.97$41.05691,474 shs$2.47 billion12/13/2024$40.38$41.08+1.73%$41.45$39.60530,558 shs$2.45 billion12/12/2024$41.00$40.38-1.51%$42.08$39.85584,351 shs$2.41 billion12/11/2024$41.60$41.00-1.44%$42.20$40.95729,155 shs$2.44 billion12/10/2024$40.50$41.60+2.72%$42.38$40.54444,708 shs$2.48 billion Get the Latest News and Ratings for PTGX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/09/2024$42.06$40.50-3.71%$42.58$40.30411,934 shs$2.41 billion12/06/2024$41.68$42.06+0.91%$42.77$41.31543,409 shs$2.51 billion12/05/2024$40.58$41.68+2.71%$43.05$40.70809,047 shs$2.48 billion12/04/2024$41.25$40.58-1.62%$42.18$40.00713,323 shs$2.42 billion12/03/2024$43.26$41.25-4.65%$43.49$41.00680,888 shs$2.46 billion12/02/2024$43.80$43.26-1.23%$43.83$42.50568,588 shs$2.58 billion11/29/2024$44.95$43.80-2.56%$45.26$43.59320,206 shs$2.61 billion11/28/2024$44.95$44.95$45.60$43.80569,522 shs$2.68 billion11/27/2024$44.83$44.95+0.27%$45.60$43.80569,522 shs$2.68 billion11/26/2024$45.53$44.83-1.54%$46.52$44.29688,248 shs$2.67 billion11/25/2024$46.46$45.53-2.00%$48.29$45.511.32 million shs$2.71 billion11/22/2024$41.65$46.46+11.54%$47.50$42.441.32 million shs$2.77 billion11/21/2024$40.65$41.65+2.47%$43.33$40.79777,894 shs$2.48 billion11/20/2024$38.65$40.65+5.17%$41.18$37.801.05 million shs$2.42 billion11/19/2024$40.39$38.65-4.31%$39.82$33.343.05 million shs$2.30 billion11/18/2024$41.11$40.39-1.75%$41.05$39.70488,766 shs$2.41 billion Related Companies Intra-Cellular Therapies Stock Price Chart Roivant Sciences Stock Price Chart Ascendis Pharma A/S Stock Price Chart Revolution Medicines Stock Price Chart Lantheus Stock Price Chart Nuvalent Stock Price Chart Blueprint Medicines Stock Price Chart Elanco Animal Health Stock Price Chart Legend Biotech Stock Price Chart Cytokinetics Stock Price Chart Receive PTGX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:PTGX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PTGX Stock Alerts